We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
    • Webinar Recordings
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Novo Nordisk Sues Over Copycat Semaglutide, Points to Serious Adverse Reactions

Novo Nordisk Sues Over Copycat Semaglutide, Points to Serious Adverse Reactions

May 31, 2024
Drugs Commercial Operations Regulatory Affairs
Novo Nordisk has sued nine more companies for selling products billed as containing semaglutide, a primary ingredient in the Danish pharma’s popular weight loss drug Wegovy.

To View This Article:

Login

Register
Forgot your password?

Subscribe To FDAnews

FDAnews Subscription

FDAnews

The trusted source for drug and device insights


Compliance — and business success — are rooted in an understanding of the top pharma, medical device and regulatory developments.

For decades, top drug and device manufacturers have relied on FDAnews’ insightful coverage with two of the industry’s most-trusted publications: Drug Industry Daily and Device Daily Bulletin Premium. These two publications have recently merged to become FDAnews, a trusted one-stop destination for drug and device insights. FDAnews delivers what you need to know each business day.

Written and reported by FDAnews’ team of experienced industry journalists and subject matter experts, each issue delivers coverage of the regulatory, legislative and business changes affecting the global drug and device industry.

Each business day, FDAnews provides valuable insights into:

  • Best practices in regulatory compliance and the pathways to approval
  • Draft and final guidances from the FDA and other regulatory agencies
  • Company mergers and technology developments
  • FDA budgets and spending, including proposals and approvals by Congress and the President
  • Quality and GMP regulatory policies and developments
  • FDA inspection policies, practices and enforcement activities
  • Global enforcement and supply chain trends
  • Pharmacovigilance developments
  • Reports and perspective on Form 483s, warning letters, recalls, FDA policy notices and other reports

New features found only in FDAnews:

  • In-depth exposés that take a deep dive into essential pharmaceutical and device issues
  • Original columns from thought leaders and former FDA officials on trending topics
  • Excerpts of best-selling FDAnews webinar and book content
  • Daily posts of breaking headlines and premium stories throughout the day on fdanews.com

FDAnews delivers precisely what you need to know each business day. It makes sense of everything successful drug and device manufacturers must know and do, delivering the news, analysis and interpretation of industry changes you need to stay in compliance and thrive.

Start your subscription to FDAnews — the trusted source for drug and device insights — today.

Subscribe today!

Start your single-user one-year subscription (250 issues) FDAnews for only $1,895.

Also available: Take advantage of our multi-user and site licenses of FDAnews, so you’ll have the most-informed workforce! Contact James DeFalco, Sales Director at jdefalco@wcgclinical.com or +1 703.538.7638 to receive a custom quote.

$1,895.00

Buy This Article Now

Add this article to your cart for $25.00

Upcoming Events

  • 13Jun

    FDA in 2024 and Beyond: What Election-Year Changes Mean for Your Business

  • 20Jun

    Inspection Readiness for EU GMP Annex 1 – Manufacture of Sterile Medicinal Products

  • 21Oct

    MAGI@home Clinical Research Conference 2024

Featured Products

  • FDA, FTC and DOJ Enforcement of Medical Device Regulations

    FDA, FTC and DOJ Enforcement of Medical Device Regulations

  • Using Real-World Evidence in Drug and Device Submissions

    Using Real-World Evidence in Drug and Device Submissions

Featured Stories

  • Risk of Hypoglycemia Trips Once-Weekly Insulin at AdComm

  • Twin Tubes and BioZorb Markers Get Recalls Designated Class I

  • Data Breach of More Than a Dozen Drugmakers Puts Patient Info at Privacy Risk

  • “Artificial Pancreas” App Cleared by FDA

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

212 Carnegie Center, Suite 301, Princeton, NJ 08540, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2024. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing